Counterfeit and Substandard Anti-infectives in Developing Countries

  • Paul N. Newton
  • Facundo M. Fernández
  • Michael D. Green
  • Joyce Primo-Carpenter
  • Nicholas J. White


There is considerable interest in optimizing the therapy for important infections in developing countries and in making the best treatments readily available and inexpensive. There is also great concern that resistance to anti-infective drugs is worsening, putting affordable treatments at risk. We argue that an important, but usually neglected aspect of these problems is drug quality. Drugs may be of poor quality if they are counterfeit, substandard or degraded. Few objective data on the prevalence of poor-quality drugs exist but surveys suggest that an alarming proportion of antimalarials and antibiotics in much of the developing world are of poor quality. For individual patients these will increase mortality and morbidity and lead to loss of faith in medicines and health systems. Counterfeit, substandard or degraded drugs with sub-therapeutic concentrations of the active ingredient or the wrong active ingredient are likely to engender the emergence and spread of resistance to these anti-infectives. Although modelling suggests that poor-quality drug should worsen drug resistance, there is sparse evidence from the field, as there has been little research. It will be very difficult to distinguish the effects of poor-drug quality and reduced patient adherence and incorrect health worker prescribing on the spread of resistance. Strengthening drug regulatory authorities, improving quality of drug production and facilitating the availability of relatively inexpensive, good-quality anti-infectives are likely to be key factors in improving drug quality.


Active Ingredient Artemisinin Derivative Drug Quality Blister Pack Counterfeit Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



PNN and NJW are supported by the Wellcome Trust and thank the WHO-Western Pacific Region and the Government of the Lao PDR for help and advice. FMF thanks WHO-Western Pacific Region and the US National Science Foundation for support. The authors thank many people for their help and for discussions, especially those at INTERPOL, USP and WPRO.


  1. Abdi, Y.A., Rimoy, G., Ericsson, O., Alm, C., and Massele, A.Y. 1995. Quality of chloroquine preparations marketed in Dar es Salaam, Tanzania. Lancet 346:1161.PubMedCrossRefGoogle Scholar
  2. Abdo-Rabbo, A., Bassili, A., and Atta, H. 2005. The quality of antimalarials available in Yemen. Malar. J. 4:28.PubMedCrossRefGoogle Scholar
  3. Alabdalla, M.A. 2005. Chemical characterization of counterfeit Captagon tablets seized in Jordan. Forensic Sci. Int. 152:185–8.PubMedCrossRefGoogle Scholar
  4. Ali, S.L. 2000. Counterfeit drugs and analytical tools for their discrimination: European perspectives. Pharm. Chem. J. 34:31–2.CrossRefGoogle Scholar
  5. Agrawal, S., Singh, I., Kaur, K.J., Bhade, S., Kaul, C.L., and Panchagnula, R. 2004. Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin. Pharmacol. Res. 50:317–27.PubMedCrossRefGoogle Scholar
  6. Ahmad, K. 2004. Antidepressants are sold as antiretrovirals in DR Congo. Lancet 363:713.PubMedCrossRefGoogle Scholar
  7. Amin, A.A., Hughes, D.A., Marsh, V., Abuya, T.O., Kokwaro, G.O., Winstanley, P.A., Ochola, S.A., and Snow, R.W. 2004. The difference between effectiveness and efficacy of antimalarial drugs in Kenya. Trop. Med. Int. Health 9:967–74.PubMedCrossRefGoogle Scholar
  8. Amin, A.A., and Snow, R.W. 2005. Brands, costs and registration status of antimalarial drugs in the Kenyan retail sector. Malar. J. 4:36.PubMedCrossRefGoogle Scholar
  9. Amin, A.A., Snow, R.W., and Kokwaro, G.O. 2005. The quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sector. J. Clin. Pharm. Ther. 30:559–65.PubMedCrossRefGoogle Scholar
  10. Anon. 2003. GlaxoSmithKline case study (7th April 2003). Judicial Protection of IPR in China. Available at: Accessed 22 February 2005.
  11. Anon. 2005. Thirteen fake bird flu vaccine-makers punished. China View, 7th November 2005. Accessed 10 January 2006.
  12. Anon. 2006. Two accused over 'fake' HIV tests. BBC News 30th October 2006. Available at: Accessed 22 August 2007.
  13. Anon. 2007a. 17 nabbed for fake rabies vaccine. Available at: Accessed 13 August 2007.
  14. Anon. 2007b. Malaria drugs recalled in Kenya. Available at: Accessed 20 August 2007.
  15. Anon. 2007c. Resistance to artemisinin derivatives along the Thai-Cambodian border. Wkly. Epidemiol. Rec. 82: 360.Google Scholar
  16. Arthur, K.E., Wolff, J.C., and Carrier, D.J. 2004. Analysis of betamethasone, dexamethasone and related compounds by liquid chromatography/electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 18:678–84.PubMedCrossRefGoogle Scholar
  17. Ashokraj, Y., Agrawal, S., Varma, M.V., Singh, I., Gunjan, K., Kaur, K.J., Bhade, S.R., Kaul, C.L., Caudron, J.M., Pinel, J., and Panchagnula, R. 2004. Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study. Int. J. Tuberc. Lung Dis. 8:1081–8.PubMedGoogle Scholar
  18. Ashokraj, Y., Kohli, G., Kaul, C.L., and Panchagnula, R. 2005. Quality control of anti-tuberculosis FDC formulations in the global market: Part II-accelerated stability studies. Int. J. Tuberc. Lung Dis. 9:1266–72.PubMedGoogle Scholar
  19. Atemnkeng, M.A., De Cock, K., and Plaizier-Vercammen, J. 2007. Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Trop. Med. Int. Health 12:68–74.PubMedGoogle Scholar
  20. Baikait R. 2003. Unsafe injections blamed for 1.3 million premature deaths annually. Pharmabiz (Mumbai) 21st May 2003.Google Scholar
  21. Ballereau, F., Prazuck, T., Schrive, I., Lafleuriel, M.T., Rozec, D., Fisch, A., and Lafaix, C. 1997. Stability of essential drugs in the field: results of a study conducted over a two-year period in Burkina Faso. Am. J. Trop. Med. Hyg. 57:31–6.PubMedGoogle Scholar
  22. Basco, L.K., Ringwald, P., Manene, A.B., and Chandenier, J. 1997. False chloroquine resistance in Africa. Lancet 350:224.PubMedCrossRefGoogle Scholar
  23. Basco, L.K. 2004. Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. Am. J. Trop. Med. Hyg. 70:245–50.PubMedGoogle Scholar
  24. Bate, R., Coticelli, P., Tren, R., and Attaran, A. 2008. Antimalarial drug quality in the most severely malarious parts of Africa – a six country study. PLoS ONE. 3:e2132.PubMedCrossRefGoogle Scholar
  25. Bogere, H., and Nafula, T. 2007. Fake quinine on the market. Daily News, 9th May 2007. Available at Accessed 10 May 2007.
  26. Bro, R. 1997. PARAFAC. Tutorial and applications. Chemom. Intell. Lab. Syst. 38:149–71.CrossRefGoogle Scholar
  27. Carter, J.F., Grundy, P.L., Hill, J.C., Ronan, N.C., Titterton, E.L., and Sleeman, R. 2004. Forensic isotope ratio mass spectrometry of packaging tapes. Analyst 129:1206–10.Google Scholar
  28. Chowdhury, M.M.H., Rana, M.S., Amin, M.N., and Faruque, A. 2004. Quality assessment of some paediatric cotrimoxazole suspensions marketed in Bangladesh. Hamdard Med. XLVII(2):58–62.Google Scholar
  29. Clough, R., Evans, P., Catterick, T., and Evans, E.H. 2006. D34s measurements of sulfur by multicollector inductively coupled plasma mass spectrometry. Anal. Chem. 78:6126–32.Google Scholar
  30. Cockburn, R., Newton, P.N., Agyarko, E.K., Akunyili, D., and White, N.J. 2005. Global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2:e100.PubMedCrossRefGoogle Scholar
  31. Craig, W.A. 2001. Does the dose matter? Clin. Infect. Dis. 33 Suppl 3:S233–7.PubMedCrossRefGoogle Scholar
  32. Day, J.N., Hien, T.T., and Farrar, J. 2004. Expiry-date tampering. Lancet 363:172.PubMedCrossRefGoogle Scholar
  33. De Veij, M., Vandenabeele, P., Alter Hall, K., Fernandez, F.M., Green, M.D., White, N.J., Dondorp, A.M., Newton, P.N., and Moens, L. 2007. Fast screening and chemical fingerprinting of counterfeit antimalarial tablets by raman spectroscopy. J. Raman Spectrosc. 38:181–7.Google Scholar
  34. Deisingh, A.K. 2005. Pharmaceutical counterfeiting. Analyst 130:271–9.PubMedCrossRefGoogle Scholar
  35. Dondorp, A.M., Newton, P.N., Mayxay M., Van Damme, W., Smithuis, F.M., Yeung, S., Petit, A., Lynam, A.J., Johnson, A., Hien, T.T., McGready, R., Farrar, J.J., Looareesuwan, S., Day, N.P.J., Green, M.D., and White N.J. 2004. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop. Med. Int. Hlth. 9:1241–6.CrossRefGoogle Scholar
  36. Drasar, P., and Moravcova, J. 2004. Recent advances in analysis of Chinese medical plants and traditional medicines. J. Chromatogr. B. 812:3–21.Google Scholar
  37. du Tetre P., and Koutouzis, M. 2006. Trafic mortel. BFC productions. Available at Accessed 22 August 2007.
  38. Eigenvector-Technologies. 2007. PLS Toolbox for Matlab. 4.1. Eigenvector Technologies: Manson.Google Scholar
  39. Eliasson, C., and Matousek, P. 2007. Noninvasive authentication of pharmaceutical products through packaging using spatially offset Raman spectroscopy. Anal. Chem. 79:1696–701.PubMedCrossRefGoogle Scholar
  40. Erhun, W.O., Babalola, O.O., and Erhun, M.O. 2001. Drug regulation and control in Nigeria: the challenge of counterfeit drugs. J. Health Popul. Dev. Ctries. 4:23–34.Google Scholar
  41. Fan, X.H., Cheng, Y.Y., Ye, Z.L., Lin, R.C., and Qian, Z.Z. 2006. Multiple chromatographic fingerprinting and its application to the quality control of herbal medicines. Anal. Chim. Acta 555:217–24.CrossRefGoogle Scholar
  42. Fackler, M. (2002) China’s fake drugs kill thousands. San Francisco Examiner, July 29.Google Scholar
  43. Fernández, F.M., Cody, R.B., Green, M., Hampton, C.Y., McGready, R., Sengaloundeth, S., White, N.J., and Newton, P.N. 2006. Characterization of solid counterfeit drug samples by desorption electrospray ionization and direct-analysis-in-real-time coupled to time-of-flight mass spectrometry. ChemMedChem 1:702–5.PubMedCrossRefGoogle Scholar
  44. Figueras, A., Pedrós, C., Valsecia, M., and Laporte, J.R. 2002. Therapeutic ineffectiveness: heads or tails? Drug Saf. 25:485–7.PubMedCrossRefGoogle Scholar
  45. Flurer, C.L., and Wolnik, K.A. 1994. Chemical profiling of pharmaceuticals by capillary electrophoresis in the determination of drug origin. J. Chromatogr. A 674:153–63.PubMedCrossRefGoogle Scholar
  46. Foster, S. 1995. Treatment of malaria outside the formal health services. Trop. Med. Hyg. 98:29–34.Google Scholar
  47. Gaudiano, M.C., Antoniella, E., Bertocchi, P., and Valvo L. 2006. Development and validation of a reversed-phase LC method for analysing potentially counterfeit antimalarial medicines. J. Pharm. Biomed. Anal. 42:132–5.Google Scholar
  48. Gaudiano, M.C., Di Maggio, A., Cocchieri, E., Antoniella, E., Bertocchi, P., Alimonti, S., and Valvo, L. 2007. Medicines informal market in Congo, Burundi and Angola: counterfeit and sub-standard antimalarials. Malar. J. 6:22.PubMedCrossRefGoogle Scholar
  49. Gilpin, R.K., and Pachla, L.A. 2005. Pharmaceuticals and related drugs. Anal. Chem. 77:3755–69.PubMedCrossRefGoogle Scholar
  50. Goossens, H., Ferech, M., Vander Stichele, R., Elseviers, M., and ESAC Project Group 2005. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365:579–87.PubMedGoogle Scholar
  51. Green, M.D., Mount, D.L., and Wirtz, R.A. 2001. Authentication of artemether, artesunate and dihydroartemisinin antimalarial tablets using a simple colorimetric method. Trop. Med. Int. Health. 6:980–2.PubMedCrossRefGoogle Scholar
  52. Green, M.D., Newton, P.N., and Fernández, F. 2003. Simple low-cost strategies to rapidly identify counterfeit drugs in developing countries, in Combating Pharmaceutical Fraud and Counterfeiting, SMI Conference Documentation. London: SMI Publishing.Google Scholar
  53. Green, M.D. 2006. Antimalarial drug resistance and the importance of drug quality monitoring. J. Postgrad. Med. 52:288–90.PubMedGoogle Scholar
  54. Green, M.D., Nettey, H., Villalba-Rojas, O., Pamanivong, C., Khounsaknalath, L., Grande Ortiz, M., Newton, P.N., Fernández, FM, Vongsack, L., and Manolin, O. 2007. Use of refractometry and colorimetry as field methods to rapidly assess antimalarial drug quality. J. Pharm. Biomed. Anal. 43:105–10.PubMedCrossRefGoogle Scholar
  55. Green, M.D., Nettey, H., and Wirtz, R.A. 2008. Determination of oseltamivir quality by colorimetric and liquid chromatographic methods. Emerg. Infect. Dis. 14, 552–6.PubMedCrossRefGoogle Scholar
  56. Greene, G. 1950. The Third Man. London: Heinemann.Google Scholar
  57. Hall, K., Newton, P.N., Green, M.D., De Veij, M., Vandenabeele, P., Pizzanelli, D., Mayxay, M., Dondorp, A., and Fernández, F. 2006. Characterization of counterfeit artesunate antimalarial tablets from SE Asia. Am. J. Trop. Med. Hyg. 75:804–11.PubMedGoogle Scholar
  58. Hanif, M., Mobarak, M.R., Ronan, A., Rahman, D., Donovan, J., and Bennish, M.L. 1995. Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. BMJ. 311:88–91.PubMedGoogle Scholar
  59. Harper, J. 2006. Counterfeit Medicines Survey Report, Council for Europe. Strasbourg: Council of Europe Publishing.Google Scholar
  60. Heath, W.J. 2004. America’s first drug regulation regime: the rise and fall of the Import Drug Act of 1848. Food Drug. Law J. 59: 169–200.PubMedGoogle Scholar
  61. Hebron, Y., Tettey, J.N., Pournamdari, M., and Watson, D.G. 2005. The chemical and pharmaceutical equivalence of sulphadoxine/pyrimethamine tablets sold on the Tanzanian market. J. Clin. Pharm. Ther. 30:575–81.PubMedCrossRefGoogle Scholar
  62. Hogerzeil, H.V., de Goeje, M.J., and Abu-Reid, I.O. 1991. Stability of essential drugs in Sudan. Lancet 338:754–5.PubMedCrossRefGoogle Scholar
  63. IMPACT (2006) Counterfeit medicines: an update on estimates. Available at: Accessed 11 August 2007.
  64. Iqbal, M., Hakimm, S.T., Hussain, A., Mirza, Z., Qureshi, F., and Abdulla, E.M.M. 2004. Ofloxacin: laboratory evaluation of the antibacterial activity of 34 brands representing 31 manufacturers available in Pakistan. Pak. J. Med. Sci. 20: 349–56.Google Scholar
  65. Issack, M.I. 2001. Substandard drugs. Lancet 358: 1463.PubMedCrossRefGoogle Scholar
  66. Jackson, Y., Chappuis, F., Loutan, L., and Taylor, W. 2006. Malaria treatment failures after artemisinin-based therapy in three expatriates: could improved manufacturer information help to decrease the risk of treatment failure ? Mal. J. 5:81.CrossRefGoogle Scholar
  67. Jähnke, R.W.O., Pachaly, P., Gobina, N.P., Schuster A., Nigge, O. J., Dwornik, K., Rubeau, V., Smine, A., Phanouvong, S., Davydova, N., Bradby, S. and Hajjou, M. 1998. Concise quality control guide on essential drugs, Vol. II, Thin Layer Chromatography. Frankfurt: German Pharma Health Fund,. Supplement 1999, 2002, 2003, and 2004.Google Scholar
  68. Jähnke, R.W.O. 2004. Counterfeit medicines and the GPHF-Minilab for rapid drug quality verification. Pharm. Ind. 66:1187–93.Google Scholar
  69. Jordan, D.D. 1993. Optical crystallographic characteristics of some USP drugs. J. Pharm. Sci. 82: 1269–71.PubMedCrossRefGoogle Scholar
  70. Kachur, S.P., Black, C., Abdulla, S., and Goodman, C. 2006. Putting the genie back in the bottle? Availability and presentation of oral artemisinin compounds at retail pharmacies in urban Dar-es-Salaam. Mal. J. 5:25.CrossRefGoogle Scholar
  71. Kayumba, P.C., Risha, P.G., Shewiyo, D., Msami, A., Masuki, G., Ameye, D., Vergote, G., Ntawukuliryayo, J.D., Remon, J.P., and Vervaet, C. 2004. The quality of essential antimicrobial and antimalarial drugs marketed in Rwanda and Tanzania: influence of tropical storage conditions on in vitro dissolution. J. Clin. Pharm. Ther. 29:331–8.PubMedCrossRefGoogle Scholar
  72. Keoluangkhot, V., Green, M., Nyadong, L., Fernández, F., Mayxay, M., and Newton, P.N. 2008. Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor quality and underdosed intramuscular artemether. Am. J. Trop. Med. Hyg. 78, 552–555.PubMedGoogle Scholar
  73. Kermode, M. 2004. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot. Int. 19:95–103.PubMedCrossRefGoogle Scholar
  74. Kishimoto, T.K., Viswanathan, K., Ganguly, T., Elankumaran, S., Smith, S., Pelzer, K., Lansing, J.C., Sriranganathan, N., Zhao, G., Galcheva-Gargova, Z., Al-Hakim, A., Bailey, G.S., Fraser, B., Roy, S., Rogers-Cotrone, T., Buhse, L., Whary, M., Fox, J., Nasr, M., Dal Pan, G.J., Shriver, Z., Langer, R.S., Venkataraman, G., Austen, K.F., Woodcock, J., and Sasisekharan, R. 2008. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 358:2457–67. 10.1056/nejmoa0803200.PubMedCrossRefGoogle Scholar
  75. Kreig, M. 1967. Black Market Medicine. Engelwood Cliffs, NJ: Prentice Hall.Google Scholar
  76. Kron, M.A. 1996. Substandard primaquine phosphate for US Peace Corps personnel. Lancet 348: 1453–4.PubMedCrossRefGoogle Scholar
  77. Laing, R., Vrakking, H., and Fourie, B. 2004. Quality and stability of TB medicines: let the buyer beware! Int. J. Tuberc. Lung Dis. 8:1043–4.PubMedGoogle Scholar
  78. Laserson, K.F., Kenyon, A.S., Kenyon, T.A., Layloff, T., and Binkin, N.J. 2001. Substandard tuberculosis drugs on the global market and their simple detection. Int. J. Tuberc. Lung Dis. 5: 448–54.PubMedGoogle Scholar
  79. Legris, C. 2005. La détection des médicaments contrefaits par investigation de leur authenticité. Étude pilote sur le marché pharmaceutique illicite de Côte d'Ivoire. Thèse pour le diplôme d'état de docteur en pharmacie soutenus à la Faculté de Pharmacie Nancy I. 2005. Available at: Accessed 11 April 2006.
  80. Lengeler, C. 2000. Insecticide-treated nets: from social marketing to national programmes. Bulletin of Medicus Mundi Switzerland No. 78, October 2000. Available at: Accessed 10 May 2007.
  81. Lindegardh, N., Hien, T.T., Farrar, J., Singhasivanon, P., White, N.J., and Day, N.P.J. 2006. A simple and rapid liquid chromatographic assay for evaluation of potentially counterfeit Tamiflu (R). J. Pharm. Biomed. Anal. 42:430–3.CrossRefGoogle Scholar
  82. Lipsitch, M., and Levin, B.R. 1997. The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41:363–73.PubMedGoogle Scholar
  83. Lipsitch, M., and Samore, M.H. 2002. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg. Infect. Dis. 8:347–54.PubMedCrossRefGoogle Scholar
  84. Lon, C.T., Tsuyuoka, R., Phanouvong, S., Nivanna, N., Socheat, D., Sokhan, C., Blum, N., Christophel, E.M., and Smine, A. 2006. Counterfeit and substandard antimalarial drugs in Cambodia. Trans. R. Soc. Trop. Med. Hyg. 100:1019–24.PubMedCrossRefGoogle Scholar
  85. Mashelkar, R.A. 2003. Report of The Expert Committee On A Comprehensive Examination Of Drug Regulatory Issues, Including The Problem Of Spurious Drugs. Ministry Of Health and Family Welfare. Government of India. Available at: Accessed 11 August 2007.
  86. Maurin, J.K., Plucinski, F., Mazurek, A.P., and Fijalek, Z. 2007. The usefulness of simple X-ray powder diffraction analysis for counterfeit control-The Viagra example. J. Pharm. Biomed. Anal. 43:1514–8.PubMedCrossRefGoogle Scholar
  87. Mulligan, K.J., Brueggemeyer, T.W., Crockett, D.F., and Schepman, J.B. 1996. Analysis of organic volatile impurities as a forensic tool for the examination of bulk pharmaceuticals. J. Chromatogr. B 686:85–95.CrossRefGoogle Scholar
  88. Nazerali, H., and Hogerzeil, H.V. 1998. The quality and stability of essential drugs in rural Zimbabwe: controlled longitudinal study. BMJ 317:512–3.PubMedGoogle Scholar
  89. Newton, P.N., Proux, S., Green, M., Smithuis, F., Rozendaal, J., Prakongpan, S., Chotivanich, K., Mayxay, M., Looareesuwan, S., Farrar, J., Nosten, F., and White, N.J. 2001. Fake artesunate in southeast Asia. Lancet 357:1948–50.PubMedCrossRefGoogle Scholar
  90. Newton, P.N., Rozendaal, J., Green, M., and White, N.J. 2002. Murder by fake drugs – time for international action. BMJ 324: 800–1.PubMedCrossRefGoogle Scholar
  91. Newton, P.N., Dondorp, A., Green, M., Mayxay, M., and White, N.J. 2003. Counterfeit artesunate antimalarials in SE Asia. Lancet 362:169.PubMedCrossRefGoogle Scholar
  92. Newton, P.N., Green, M.D., Fernández, F.M., Day, N.P.J., and White, N.J. 2006a. Counterfeit anti-infective medicines. Lancet Inf. Dis. 6: 602–13.Google Scholar
  93. Newton, P.N., McGready, R., Fernández, F.M., Green, M.D., Sunjio, M., Bruneton, C., Phanouvong, S, Millet, P., Whitty, C.J., Talisuna, A.O., Proux, S., Christophel, E.M., Malenga, G., Singhasivanon, P., Bojang, K., Kaur, H., Palmer, K., Day, N.P.J., Greenwood, B.M., Nosten, F., and White, N.J. 2006b. Manslaughter by fake artesunate in Asia -will Africa be next ? PLoS Med. 3:e197Google Scholar
  94. Newton, P.N., Cockburn, R., and White, N.J. 2007. E-letter to submit in response to “The global threat of counterfeit drugs: why industry and governments must communicate.” PLoS Med..
  95. Newton, P.N., Fernández, F.M., Plançon, A., Mildenhall, D.C., Green, M.D., Ziyong, L., Christophel, E.M., Phanouvong, S., Howells, S., McIntosh, E., Laurin, P., Blum, N., Hampton, C.Y., Faure, K., Nyadong, L., Soong, S.W.R., Santoso, B., Zhiguang, W., Newton, J., and Palmer, K. 2008. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med. 5: e32PubMedCrossRefGoogle Scholar
  96. Nyadong, L., Green, M., De Jesus, V., Newton, P.N., and Fernandez, F.M. 2007. Reactive desorption electrospray ionization linear ion trap mass spectrometry of latest-generation counterfeit antimalarials via non-covalent complex formation. Anal. Chem. 79:2150–57.Google Scholar
  97. Ogwal-Okeng, J.W., Okello, D.D.O., and Odyek, O. 1998. Quality of oral and parenteral chloroquine in Kampala. East Afr. Med. J. 75:692–4.PubMedGoogle Scholar
  98. Okeke, I.N., Lamikanra, A., and Edelman, R. 1999. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg. Inf. Dis. 5:18–27.CrossRefGoogle Scholar
  99. Okeke, I.N., Klugman, K.P., Bhutta, Z.A., Duse, A.G., Jenkins, P., O'Brien, T.F., Pablos-Mendez, A., and Laxminarayan, R. 2005a. Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect. Dis. 5:568–80.Google Scholar
  100. Okeke, I.N., Laxminarayan, R., Bhutta, Z.A., Duse, A.G., Jenkins, P., O'Brien, T.F., Pablos-Mendez, A., and Klugman, K.P. 2005b. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect. Dis. 5:481–93.Google Scholar
  101. Payne, D. 1988. Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? Parasitol. Today 4: 112–5.PubMedCrossRefGoogle Scholar
  102. Petralanda, I. 1995. Quality of antimalarial drugs and resistance to Plasmodium vivax in Amazonian region. Lancet 345:1433.PubMedCrossRefGoogle Scholar
  103. Phanouvong, S. 2003. Registration, inspection and testing: how to prioritise. SEAM Conference, Da es salaam, Tanzania. Dec 10–12th, 2003. Accessed 9 December 2005.
  104. The Pharmacy and Poisons Board, Republic of Kenya Ministry of Health. 2007. Available at: Accessed 22 August 2007.
  105. Prazuck, T., Falconi, I., Morineau, G., Bricard-Pacaud, V., Lecomte, A., and Ballereau, F. 2002. Quality control of antibiotics before the implementation of an STD program in Northern Myanmar. Sex. Transm. Dis. 29:624–7.PubMedCrossRefGoogle Scholar
  106. Price, R.N., and Nosten, F. 2001. Drug resistant falciparum malaria: clinical consequences and strategies for prevention. Drug. Resist. Update 4:187–96.CrossRefGoogle Scholar
  107. Primo-Carpenter, J. 2004. A review of drug quality in Asia with focus on anti-infectives. USP. Available at: Accessed 9 August 2007.
  108. Primo-Carpenter, J., and McGinnis, M. 2007. A matrix of drug quality reports on USAID-assisted countries by the USP Drug Quality and Information Program, 2007. Accessed 9 August 2007.
  109. Rago, L. 2002. Counterfeit drugs: threat to public health. Global Forum Pharmaceutical AntiCounterfeiting, Geneva, Switzerland, 22–25th September 2002.Google Scholar
  110. Rao, K.V., Eidus, L., Evans, C., Kailasam, S., Radhakrishna, S., Somasundaram, P.R., Stott, H., Subbammal, S., and Tripathy, S.P. 1968. Deterioration of cycloserine in the tropics. Bull. World Health Organ. 39:781–9.PubMedGoogle Scholar
  111. Raufu, A. 2002. Influx of fake drugs to Nigeria worries health experts. BMJ 324:698.PubMedCrossRefGoogle Scholar
  112. Raufu, A. 2003. India agrees to help Nigeria tackle the import of fake drugs. BMJ 326:1234.PubMedCrossRefGoogle Scholar
  113. Reidenberg, M.M., and Conner, B.A. 2001. Counterfeit and substandard drugs. Clin. Pharmacol. Ther. 69: 189–93.PubMedCrossRefGoogle Scholar
  114. Ricci, C., Nyadong, L., Fernández, F.M., Newton, P.N., and Kazarian, S. 2007. Combined Fourier transform infrared imaging and desorption electrospray ionization linear ion trap mass spectrometry for the analysis of counterfeit antimalarial tablets. Anal. Bioanal. Chem. 387:551–9.PubMedCrossRefGoogle Scholar
  115. Risha, P.G., Shewiyo, D., Msami, A, Masuki, G., Vergote, G., Vervaet, C., and Remon, J.P. 2002. In vitro evaluation of the quality of essential drugs on the Tanzanian market. Trop. Med. Int. Hlth. 7:701–7.CrossRefGoogle Scholar
  116. Rookkapan, K., Chongsuvivatwong, V., Kasiwong, S., Pariyawatee, S., Kasetcharoen, Y., and Pungrassami, P. 2005. Deteriorated tuberculosis drugs and management system problems in lower southern Thailand. Int. J. Tuberc. Lung Dis. 9:654–60.PubMedGoogle Scholar
  117. Rozendaal, J. 2000. Fake antimalarials circulating in Cambodia. Mekong Malar. Forum 7:62–9.Google Scholar
  118. Sanderson, K. 2006. Fake pesticides pose threat – flood of counterfeit chemicals is harming people and industry. Nature. 5th November 2006. doi:10.1038/news061030-14.Google Scholar
  119. Saywell, T., and McManus, J. 2002. What’s in that pill? Far East. Econ. Rev. Feb 21st 2002: 34–40.Google Scholar
  120. Scafi S.H.F., and Pasquini, C. (2001). Identification of counterfeit drugs using near-infrared spectroscopy. Analyst 126:2218–24.Google Scholar
  121. Schwartz, E., Regev-Yochay, G., and Kurnik, D. 2000. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 62:393–5.PubMedGoogle Scholar
  122. Shakoor, O., Taylor, R.B., and Behrens, R.H. 1997. Assessment of the incidence of substandard drugs in developing countries. Trop. Med. Int. Hlth. 2:839–45.CrossRefGoogle Scholar
  123. Shen, H., Carter, J.F., Brereton, R.G., and Eckers, C. 2003. Discrimination between tablet production methods using pyrolysis-gas chromatography-mass spectrometry and pattern recognition. Analyst 128:287–92.PubMedCrossRefGoogle Scholar
  124. Shwe, T.N., Nyein, M.M., Yi, W., and Mon, A, 2002. Blood culture isolates from children admitted to Medical Unit III, Yangon Children's Hospital, 1998. Southeast Asian J. Trop. Med. Pub. Health. 33:764–71.Google Scholar
  125. Smine, A., Diouf, K., and Blumm, N.L. 2002. Antimalarial drug quality in Senegal. USP DQI. Available at: Accessed 23 October 2006.
  126. Stepniewska, K., and White, N.J. 2008. The pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother. 52:1589–96.PubMedCrossRefGoogle Scholar
  127. Sunenshine, R.H., Tan, E.T., Terashita, D.M., Jensen, B.J., Kacica, M.A., Sickbert-Bennett, E.E., Noble-Wang, J.A., Palmieri, M.J., Bopp, D.J., Jernigan, D.B., Kazakova, S., Bresnitz, E.A., Tan, C.G., and McDonald, L.C. 2007. A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy. Clin. Inf. Dis. 45:527–33.CrossRefGoogle Scholar
  128. Tan. T.Q., Mason, E.O. Jr, and Kaplan, S.L. 1993. Penicillin-resistant systemic pneumococcal infections in children: a retrospective case-control study. Pediatrics 92:761–7.PubMedGoogle Scholar
  129. Taylor, R.B., Shakoor, O., and Behrens, R.H. 1995. Drug quality, a contributor to drug resistance? Lancet. 346:122.PubMedCrossRefGoogle Scholar
  130. Taylor, R.B., Shakoor, O., Behrens, R.H., Everard, M., Low, A.S., Wangboonskul, J., Reid, R.G., and Kolawole, J.A. 2001. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 357:1933–6.PubMedCrossRefGoogle Scholar
  131. ten Ham, M. 1992. Counterfeit drugs: implications for health. Adv. Drug. React. Toxicol. Rev. 11: 59–65.Google Scholar
  132. Thomas, J.K., Forrest, A., Bhavnani, S.M., Hyatt, J.M., Cheng, A., Ballow, C.H., and Schentag, J.J. 1998. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob.. Agents Chemother. 42:521–7.PubMedGoogle Scholar
  133. Tillson, A.H., and Eisenberg, W.V. 1954. Tables for the identification of N.F.X crystalline substances by the microscopic-crystallographic method. J. Pharm. Sci. 43: 760–7.CrossRefGoogle Scholar
  134. USP. 2004. Fake antimalarials found in Yunnan Province, China, 2004. Available at: Accessed 9 December 2005.
  135. White, N.J. 1999. Antimalarial drug resistance and combination chemotherapy. Phil. Trans. R. Soc. Lond. B 354: 739–49.CrossRefGoogle Scholar
  136. White, N.J., and Pongtavornpinyo, W. 2003. The de novo selection of drug-resistant malaria parasites. Proc. R. Soc. Lond. B Biol. Sci. 270:545–54.CrossRefGoogle Scholar
  137. White, N.J. 2004. Antimalarial drug resistance. J. Clin. Invest. 113:1084–92.PubMedGoogle Scholar
  138. Whitney, C.G., Farley, M.M., Hadler, J., Harrison, L.H., Bennett, N.M., Lynfield, R., Reingold, A., Cieslak, P.R., Pilishvili, T., Jackson, D., Facklam, R.R., Jorgensen, J.H., Schuchat, A. and Active Bacterial Core Surveillance of the Emerging Infections Program Network. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348: 1737–46.PubMedCrossRefGoogle Scholar
  139. Wold, S., Esbensen, K., and Geladi, P. 1987. Principal component analysis. Chemom. Intell. Lab. Syst. 2:37–52.CrossRefGoogle Scholar
  140. Wolff, J.C., Thomson, L.A., and Eckers, C. 2003. Identification of the 'wrong' active pharmaceutical ingredient in a counterfeit Halfan™ drug product using accurate mass electrospray ionisation mass spectrometry, accurate mass tandem mass spectrometry and liquid chromatography/mass spectrometry. Rapid Comm. Mass Spect. 17: 215–21.CrossRefGoogle Scholar
  141. Wondemagegnehu, E. 1999. Counterfeit and substandard drugs in Myanmar and Viet Nam. WHO Report. WHO/EDM/QSM/99.3. Geneva: WHO.Google Scholar
  142. World Health Organisation. 1999. Counterfeit drugs – guidelines for the development of measures to combat counterfeit drugs. WHO/EDM/QSM/99.1. Geneva: WHO.Google Scholar
  143. World Health Organisation 2000. World Health Organisation Counterfeit drug reports: 1999–October 2000. Available at: Accessed 17 June 2003.
  144. WHO 2003. Counterfeit triple antiretroviral combination product (Ginovir 3D) detected in Cote d’ Ivoire. WHO QSM/MC/IEA.110, Nov. 28, 2003. Available at: Accessed 4 April 2008.
  145. World Health Organisation. 2005. Counterfeit and substandard drugs. Frequently asked questions. Available at: Accessed 1 December 2005.
  146. Yeung, S., and White, N.J. 2005. How do patients use antimalarial drugs? A review of the evidence. Trop. Med. Int. Health 10:121–38.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Paul N. Newton
    • 1
    • 2
  • Facundo M. Fernández
    • 3
  • Michael D. Green
    • 4
  • Joyce Primo-Carpenter
    • 5
  • Nicholas J. White
    • 1
    • 2
    • 6
  1. 1.Wellcome Trust–Mahosot Hospital–Oxford Tropical Medicine Research Collaboration, Microbiology LaboratoryMahosot HospitalVientianeLao PDR
  2. 2.Centre for Tropical Medicine, Churchill HospitalUniversity of OxfordOxfordUK
  3. 3.School of Chemistry and BiochemistryGeorgia Institute of TechnologyAtlantaUSA
  4. 4.Division of Parasitic DiseasesCenters for Disease Control & PreventionAtlantaUSA
  5. 5.U.S. Pharmacopeia, Drug Quality and Information ProgramRockvilleUSA
  6. 6.Mahidol UniversityBangkokThailand

Personalised recommendations